EP Patent

EP4103717A4 — Compositions and methods for inducible alternative splicing regulation of gene expression

Assigned to Childrens Hospital of Philadelphia CHOP · Expires 2024-02-28 · 2y expired

What this patent protects

Patent listed against nusinersen-sodium.

Drugs covered by this patent

nusinersen-sodium (NUSINERSEN SODIUM)

Patent Metadata

Patent number: EP4103717A4
Jurisdiction: EP
Classification: —
Expires: 2024-02-28
Drug substance claim: No
Drug product claim: No
Assignee: Childrens Hospital of Philadelphia CHOP
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.